Contact Us
Drug Search Results
More Filters [+]

Biolimus

Alternative Names: biolimus
Latest Update: 2024-05-07
Latest Update Note: PubMed Publication

Product Description

The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01137019)

Mechanisms of Action: Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Colombia | United Arab Emirates

Approved Indications: None

Known Adverse Events: None

Company: Biosensors Europe
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Biolimus

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Coronary Artery Disease|Myocardial Ischemia|Dyslipidemia|Hypertension|Angina, Stable|ST Elevation Myocardial Infarction|Acute Coronary Syndrome|Myocardial Infarction|Thrombosis|Inflammation|Stroke

Phase 3: Coronary Artery Disease|Myocardial Ischemia|Coronary Disease

Phase 2: Coronary Thrombosis|Coronary Artery Disease|Myocardial Ischemia|ST Elevation Myocardial Infarction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ChiCTR2000041438

N/A

Recruiting

Coronary Disease

2025-12-31

JW-PM-DCB-2024

N/A

Not yet recruiting

Coronary Artery Disease|Myocardial Ischemia

2025-12-30

REFORM

N/A

Unknown status

Coronary Restenosis|Coronary Artery Disease|Coronary Stenosis

2023-04-01

SORTOUTXI

N/A

Active, not recruiting

Coronary Artery Disease

2023-03-19

Recent News Events

Date

Type

Title

05/07/2024

PubMed

 Biolimus-coated versus paclitaxel-coated balloons for coronary in-stent restenosis (BIO ASCEND ISR): a randomised, non-inferiority trial.

02/01/2024

PubMed

 Long-term outcomes after coronary intervention with biodegradable polymer stents in patients with acute coronary syndromes.

01/16/2024

PubMed

 Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.

03/10/2023

News Article

 Coronary Stents Market to Surpass US$ 20,423.0 Million by 2030, Says Coherent Market Insights (CMI)

10/27/2022

News Article

 Global Drug Eluting Stents Market to Surpass US$ 4,844.6 Million by 2030, Says Coherent Market Insights (CMI)

02/02/2022

News Article

 Global Drug-Eluting Stents Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts

01/28/2022

News Article

 Outlook on the Drug-Eluting Stents Global Market to 2027 - by Coating, Drug, Stent Platform, Generation, Application, End-user and Region

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions